Evaluating Buspirone to Treat Opioid Withdrawal
Recruiting
Phase 2
Interventional Study
Opioid Use Disorder
Opioid Withdrawal
Opioid Craving
Anxiety
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The investigators propose a rigorous, Phase II, three-group, placebo-controlled double-blind randomized controlled trial (RCT) to evaluate the efficacy of buspirone for both withdrawal and craving among individuals with opioid use disorder (OUD) undergoing a standardized stepwise taper. During this 10 to 12-day residential study, participants with OUD will be enrolled, stabilized on a short-acting…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Aged 18-75
* Opioid positive urine sample
* Current moderate-severe opioid use disorder with evidence of physical dependence
* Interested in undergoing opioid detoxification
Exclusion Criteria:
* Being pregnant or breastfeeding
* Enrolled in methadone or buprenorphine mainte…
Contacts